The clinical utility of long-term humidification therapy in chronic airway disease

Respiratory Medicine

Volumn 104, Issue 4, 2010, Pages 525-533

  Rea, Harold ^a   McAuley, Sue ^b   Jayaram, Lata ^b   Garrett, Jeffrey ^b   Hockey, Hans ^c   Storey, Louanne ^b   O'Donnell, Glenis ^b   Haru, Lynne ^b   Payton, Matthew ^d   O'Donnell, Kevin ^d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b MIDDLEMORE HOSPITAL   (New Zealand)

^c Biometrics Matters Ltd   (New Zealand)

^d Fisher and Paykel Healthcare Ltd ^*  (New Zealand)

Author keywords

Bronchiectasis; COPD; Humidification therapy; Mucociliary clearance

Indexed keywords

ADULT; AGED; ARTICLE; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; EXERCISE; HUMAN; HUMIDIFIER; LONG TERM CARE; LUNG FUNCTION; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; TREATMENT OUTCOME; ARTIFICIAL VENTILATION; DEVICES; DISEASE COURSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMIDITY; LUNG FUNCTION TEST; MALE; MORTALITY; NEW ZEALAND; OXYGEN THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UTILIZATION;

AGED; BRONCHIECTASIS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HUMIDITY; MALE; NEW ZEALAND; OXYGEN INHALATION THERAPY; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; RESPIRATORY THERAPY; TREATMENT OUTCOME;

EID: 77349126034     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.12.016     Document Type: Article

References (30)

1. Bhowmik A., Seemungal T.A., Sapsford R.J., Devalia J.L., and Wedzicha J.A. Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax 53 11 (1998 Nov) 953-956
2. Donaldson G.C., Seemungal T.A., Bhowmik A., and Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 10 (2002 Oct) 847-852
3. Fuschillo S., De Felice A., and Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 31 2 (2008 Feb) 396-406
4. Prescott E., Lange P., and Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 8 8 (1995 Aug) 1333-1338
5. Rogers D.F. Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy. Monaldi Arch Chest Dis 55 4 (2000 Aug) 324-332
6. Martinez-Garcia M.A., Perpina-Tordera M., Roman-Sanchez P., and Soler-Cataluna J.J. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 128 2 (2005 Aug) 739-745
7. Wolkove N., Kamel H., Rotaple M., and Baltzan Jr. M.A. Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD. Chest 121 3 (2002 Mar) 702-707
8. Daviskas E., Anderson S.D., Gomes K., Briffa P., Cochrane B., Chan K., et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 10 1 (2005) 46-56
9. Daviskas E., Anderson S.D., Young I.H., Lassig A., and Charlton B. A placebo controlled trial with inhaled mannitol improves health related quality of life in patients with bronchiectasis. Eur Respir J 24 Suppl. 48 (2004) 707s
10. Hasani A., Chapman T.H., McCool D., Smith R.E., Dilworth J.P., and Agnew J.E. Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis. Chron Respir Dis 5 2 (2008) 81-86
11. Mall M.A., Harkema J.R., Trojanek J.B., Treis D., Livraghi A., Schubert S., et al. Development of chronic bronchitis and emphysema in {beta}-epithelial Na+ channel-overexpressing mice. Am J Respir Crit Care Med 177 7 (2008 April) 730-742
12. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004 Jun) 932-946
13. Barker A.F. Bronchiectasis. N Engl J Med 346 18 (2002 May 2) 1383-1393
14. Fletcher C.M.E.P., Fairbairn M.B., et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 2 (1959) 257-266
15. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 26 (2005) 319-338
16. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J Suppl 16 (1993 Mar) 5-40
17. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 1 (2002 Jul) 111-117
18. Jones P.W., Quirk F.H., Baveystock C.M., and Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's respiratory questionnaire. Am Rev Respir Dis 145 6 (1992 Jun) 1321-1327
19. Jones P.W. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 19 3 (2002 Mar) 398-404
20. Efthimiadis A., Spanevello A., Hamid Q., Kelly M.M., Linden M., Louis R., et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl 37 (2002 Sep) 19s-23s
21. Burge S., and Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 41 (2003 Jun) 46s-53s
22. Groves N., and Tobin A. High flow nasal oxygen generates positive airway pressure in adult volunteers. Aust Crit Care 20 4 (2007 Nov) 126-131
23. Brack T., Senn O., Russi E.W., and Bloch K.E. Transtracheal high-flow insufflation supports spontaneous respiration in chronic respiratory failure. Chest 127 1 (2005 Jan) 98-104
24. Aaron S.D., Fergusson D., Marks G.B., Suissa S., Vandemheen K.L., Doucette S., et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 63 2 (2008 Feb) 122-128
25. Jones P., and Higenbottam T. Quantifying of severity of exacerbations in chronic obstructive pulmonary disease: adaptations to the definition to allow quantification. Proc Am Thorac Soc 4 8 (2007) 597-601
26. Aaron S.D., Vandemheen K.L., Fergusson D., Maltais F., Bourbeau J., Goldstein R., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 146 8 (2007 April) 545-555
27. Calverley P.M.A., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 8 (2007) 775-789
28. Dysart K., Miller T.L., Wolfson M.R., and Shaffer T.H. Research in high flow therapy: mechanisms of action. Respir Med 103 10 (2009) 1400-1405
29. Tsolaki V., Pastaka C., Karetsi E., Zygoulis P., Koutsokera A., Gourgoulianis K.I., et al. One-year non-invasive ventilation in chronic hypercapnic COPD: effect on quality of life. Respir Med 102 6 (2008 Jun) 904-911
30. O'Brien C., Guest P.J., Hill S.L., and Stockley R.A. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 55 8 (2000 Aug) 635-642